Effectiveness of combined therapy of neovascular age-related macular degeneration using anti-VEGF drug aflibercept and nutraceutical «Resvega Forte»
Authors:   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Danilova L.P. ,   Postgraduate Institute for Public Health Workers, Khabarovsk, Russian Federation, Egorov V.V. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation,   Postgraduate Institute for Public Health Workers, Khabarovsk, Russian Federation, Smoliakova G.P. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation,   Postgraduate Institute for Public Health Workers, Khabarovsk, Russian Federation, Povalyaeva D.А. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Zhajvoronok N.S. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Udovichenko Е.V. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Emanova L.P. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation
Published: June 2021

Purpose. To evaluate the clinical efficacy of using the angiogenesis inhibitor aflibercept in combination with the nutraceutical «Resvega Forte» in the treatment of neovascular age-related macular degeneration (nAMD) Material and methods. The clinical study involved 25 patients (25 eyes) with nAMD, who received 3 «loading» intravitreal injections of aflibercept (IIA) 2.0 mg (0.05 ml) at intervals of 1 time per month. Further, during the year, all patients received therapy according to the «heal and extend the interval» protocol. The patients of the main group (14 people) were supplemented with triple IIA with the administration of the «Resvega Forte» complex, 1 capsule 2 times a day for three months and then, after 6 months, continued with a second course. Patients of the comparison group (11 persons) did not receive the «Resvega Forte» complex. The central retinal thickness (CRT), the presence of detachment of the retinal pigment epithelium and neuroepithelium, subretinal, intraretinal or fluid under the pigment epithelium were assessed. Results. By the 12th month of observation, none of the patients of the main group against the background of two complexes «Resvega Forte» was found to have a resumption of disease activity. The maximum corrected visual acuity increased 3 times and amounted to 0.75±0.03 compared to the initial 0.25±0.06. The circulatory system in these patients on average corresponded to the norm – 254.6±11.3 µm. In the comparison group, the resumption of disease activity was noted twice, which was accompanied by a decrease in the functional and morphological parameters of the retina. Conclusion. The inclusion of the nutraceutical «Resvega Forte» in the treatment regimen allows not only to reduce the risk of progression of nAMD, but also to increase the functional and morphological parameters of the retina. An integrated approach makes it possible to increase the interval between injections and reduce the required number of them without additional monitoring, which reduces the burden on both the patient and the doctor. Key words: neovascular age-related macular degeneration, aflibercept, nutraceutical «Resvega forte».